AiCuris Anti-infective Cures AG
10
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
10.0%
1 terminated/withdrawn out of 10 trials
87.5%
+1.0% vs industry average
10%
1 trials in Phase 3/4
86%
6 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Study to Understand How a New, Unlicensed Drug (AIC468) Works, Compared With a Placebo, Against BK Virus in Patients Who Have Had a Kidney Transplant.
Role: lead
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects
Role: lead
Thorough QT/QTc of Pritelivir in Healthy Subjects
Role: lead
Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects with Treatment Resistant Herpes Simplex Virus Type 1 or 2
Role: lead
Potential Influence of Esomeprazole on the Pharmacokinetics of Pritelivir
Role: lead
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
Role: lead
Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2
Role: lead
Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes
Role: lead
Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients
Role: lead
Study to Assess Management and Outcomes of Hospitalised Patients With Complicated UTI (RESCUING)
Role: collaborator
All 10 trials loaded